Skip to main content
logo
Rohto Pharmaceutical Co.,Ltd. (TYO:4527)
Japan flag Japan · Delayed Price · Currency is JPY
2,866.50
-0.50 (-0.02%)
Aug 21, 2026, 3:30 PM JST

Rohto Pharmaceutical Cash Flow Statement

Millions JPY. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
46,82142,33141,51834,29027,953
Depreciation & Amortization
17,37713,1438,6877,8017,673
Loss (Gain) From Sale of Assets
431753481,338892
Loss (Gain) From Sale of Investments
907-1,896798285798
Loss (Gain) on Equity Investments
-92-166289-56-143
Other Operating Activities
-11,992-10,932-10,218-6,995-10,347
Change in Accounts Receivable
-5,1841,950-6,787-7,560-30
Change in Inventory
-2,069-4,597-4,029-6,105-3,061
Change in Accounts Payable
-141-1,2881,6791,7163,323
Change in Other Net Operating Assets
2,118-1,8031,9606,210192
Operating Cash Flow
47,78836,91734,24530,92427,250
Operating Cash Flow Growth
29.45%7.80%10.74%13.48%36.20%

Investing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-11,494-9,080-7,979-8,473-10,267
Sale of Property, Plant & Equipment
262627210912
Cash Acquisitions
--74,479---1,203
Sale (Purchase) of Intangibles
-14,757-1,481-933-1,435-1,061
Investment in Securities
-3,282-3,563-7,376-3,299-3,652
Other Investing Activities
-60163230178128
Investing Cash Flow
-29,780-89,170-16,317-13,176-16,406

Financing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
2,638-656-1,273
Long-Term Debt Issued
1,84740,1781,6052209,450
Total Debt Issued
4,48540,1782,26122010,723
Short-Term Debt Repaid
--2,310--1,341-
Long-Term Debt Repaid
-2,607-5,961-3,484-8,761-3,133
Total Debt Repaid
-2,607-8,271-3,484-10,102-3,133
Net Debt Issued (Repaid)
1,87831,907-1,223-9,8827,590
Repurchase of Common Stock
--5,000---
Common Dividends Paid
-9,264-7,072-5,475-4,676-3,422
Other Financing Activities
-4,45915,484-7,086-1,641-698
Financing Cash Flow
-11,84535,319-13,784-16,1993,470

Net Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
3,3253,3744,7035,2364,335
Miscellaneous Cash Flow Adjustments
1422192311
Net Cash Flow
9,630-13,3418,8706,78618,650

Free Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
36,29427,83726,26622,45116,983
Free Cash Flow Growth
30.38%5.98%16.99%32.20%50.47%
Free Cash Flow Margin
10.56%9.02%9.70%9.41%8.51%
Free Cash Flow Per Share
154.14121.61114.8098.1374.23
Levered Free Cash Flow
9,05916,65115,30112,45011,698
Unlevered Free Cash Flow
9,86117,24415,42312,60411,853

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
1,307888200247228
Cash Income Tax Paid
11,92211,2199,9706,9378,731
Change in Working Capital
-5,276-5,738-7,177-5,739424